Adverse events following immunization: Findings from 2017/2018 measles vaccination campaign, Nigeria AEFI reporting in 2017/2018 measles vaccination campaign.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
17 11 2021
Historique:
received: 29 03 2020
revised: 19 02 2021
accepted: 26 02 2021
pubmed: 15 3 2021
medline: 11 3 2022
entrez: 14 3 2021
Statut: ppublish

Résumé

An Adverse event following immunization (AEFI) is an untoward medical occurrence following immunization and which may not have a necessary causal relationship with the usage of a vaccine. The World Health Organization categories AEFI into two; serious and non-serious. An AEFI is considered serious if it is life-threatening, requires inpatient hospitalization or results in death. The measles vaccine is safe and effective however because it is a live-attenuated injectable vaccine it is more prone to AEFI as compared to non-injectable vaccines when given in large numbers over a short period as is the nature of measles mass vaccination campaigns (MVC). This article describes Nigeria's experience on AEFI reporting during the 2017/2018 Measles vaccination campaign (MVC). We reviewed various materials which included the Open Data Kit (ODK) which is an open source smartphone-based data collecting tool, operations room reports, measles campaign tally sheets, AEFI line listing forms, the post measles campaign coverage survey report and the report of the AEFI national expert committee review of the 2017/2018 Nigeria measles MVC. A total of 6,214 suspected cases of AEFI were line listed from all 36 states and the Federal Capital Territory(FCT) during the 2017/2018 MVC with Fever(38%) and pain at injection site the (30%)most common reports. Overall, 99.7% AEFIs were reported to be non-serious AEFIs, with almost all cases resolved fully with no long-term sequalae.. The national incidence of suspected AEFI per 100,000 population was 16.3 with subnational incidence highest in Kebbi state (101.3/100,000) and lowest in Bayelsa state (0.8/100,000). Adequate AEFI reporting, Investigation and management remains important in managing the risk of a disruption of mass campaigns. The deployment of supervisors during campaign may play an important role in improving the identification and reporting of suspected AEFI. Further inquiries about AEFIs during the post campaign coverage evaluation also played a role in improving AEFI reporting and documentation. The real-time, on the spot, follow up by the national operations team helped with decision making and intervention including AEFI investigations and assessments.

Identifiants

pubmed: 33714655
pii: S0264-410X(21)00258-9
doi: 10.1016/j.vaccine.2021.02.067
pii:
doi:

Substances chimiques

Measles Vaccine 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

C82-C88

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Ene Gbenewei (E)

National Primary Health Care Development Agency, Nigeria.

Terna Nomhwange (T)

World Health Organization Country Office Nigeria, Nigeria. Electronic address: nomhwanget@who.int.

Lydia Taiwo (L)

AFENET Country Office Nigeria, Nigeria.

Isiaka Ayodeji (I)

World Health Organization Country Office Nigeria, Nigeria.

Kabir Yusuf (K)

National Primary Health Care Development Agency, Nigeria.

Anne E Jean Baptiste (AE)

World Health Organization Country Office Nigeria, Nigeria.

Peter Nsubuga (P)

Global Health Solutions, Atlanta, GA, USA.

Fiona Braka (F)

World Health Organization Country Office Nigeria, Nigeria.

Joseph Oteri (J)

National Primary Health Care Development Agency, Nigeria.

Faisal Shuaib (F)

National Primary Health Care Development Agency, Nigeria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH